Market Overview:
The global alcoholic hepatitis therapeutic market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of alcoholic hepatitis, rising awareness about available treatment options, and growing demand for better-quality therapies. Based on type, the global alcoholic hepatitis therapeutic market is segmented into monoclonal antibodies, caspase protease inhibitors, corticosteroids, hemorheologic agents, anabolic steroids, hepatotropic hormones, sulfhydryl agents and others. Monoclonal antibodies are expected to account for the largest share of this market in 2018 owing to their high efficacy and safety profile. Based on application, hospitals and clinics are expected to account for the largest share of this market in 2018 followed by research and development laboratories.
Product Definition:
Alcoholic hepatitis is a liver disease caused by alcohol abuse. It is the most common form of hepatitis in the United States. Symptoms include fever, jaundice, and abdominal pain. Treatment includes abstinence from alcohol and medications to help relieve symptoms. Alcoholic hepatitis therapy is important because it can help prevent further damage to the liver and improve the patient's prognosis.
Monoclonal Antibodies:
Monoclonal Antibodies are antibodies produced by the body's immune system in response to a specific injury or infection. They are specifically designed to target and attach themselves to harmful substances (antigens) and bring about cellular destruction. Monoclonal Antibodies can also attach themselves to cancer cells, thusly inhibiting their growth & functioning.
Caspase Protease Inhibitor:
Caspase protease inhibitor is a drug that prevents the activity of caspases, an enzyme responsible for cell death. Caspase inhibitors are used in the treatment and prophylaxis of diseases such as pancreatitis, cystic fibrosis, and cancer. The drug has been approved by FDA to treat patients with acute alcoholic hepatitis who have developed complications that include jaundice and elevated liver enzymes but are not responding to conventional treatments (hepatitis therapy).
Application Insights:
Based on application, the global market is segmented into hospitals and clinics, research and development centers, and others. Hospitals and clinics dominated the market in 2017 owing to factors such as increasing prevalence of alcoholic liver disease coupled with rising awareness about treatment options among patients. Furthermore, hospital-based programs that focus on providing early diagnosis along with effective treatment for AALD are also driving demand for therapeutics in this segment.
Research & development centers accounted for a significant share of revenue in 2017 due to high R&D investments by companies pertaining to new drug development for the treatment of alcoholic liver disease. For instance, In April 2018 Pfizer Inc.
Regional Analysis:
Europe dominated the global market in 2017. The presence of key manufacturers and well-established healthcare infrastructure are some factors responsible for its large share. Furthermore, rising incidence of alcoholic hepatitis is another factor contributing to its largest share. According to a study published by World Health Organization (WHO) in 2018, more than 90,000 new cases were reported from Europe in 2014; however, the number is likely to be higher considering that only 50% of patients with alcohol-related disorders seek treatment at hospitals and clinics.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing prevalence of lifestyle diseases such as cardiovascular diseases.
Growth Factors:
- Increasing incidence of alcoholic hepatitis across the globe
- Growing awareness about the disease and its treatment options among patients and healthcare professionals
- Rising demand for better and more effective therapies for alcoholic hepatitis
- increasing research and development activities in this area
- growing number of clinical trials being conducted for novel therapeutic agents for alcoholic hepatitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Alcoholic Hepatitis Therapeutic Market Research Report
By Type
Monoclonal Antibodies, Caspase Protease Inhibitor, Corticosteroids, Hemorheologic Agents, Anabolic Steroids, Hepatotropic Hormones, Sulfhydryl Agents, Others
By Application
Hospitals and Clinics, Research and Development
By Companies
Alkermes, Conatus pharmaceuticals, Dainippon sumitomo pharma, Generon corporation, Immuron limited, Lupin Laboratories, Intercept Pharmaceuticals, Teva Pharmaceuticals, Sanofi-Aventis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Alcoholic Hepatitis Therapeutic Market Report Segments:
The global Alcoholic Hepatitis Therapeutic market is segmented on the basis of:
Types
Monoclonal Antibodies, Caspase Protease Inhibitor, Corticosteroids, Hemorheologic Agents, Anabolic Steroids, Hepatotropic Hormones, Sulfhydryl Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Research and Development
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alkermes
- Conatus pharmaceuticals
- Dainippon sumitomo pharma
- Generon corporation
- Immuron limited
- Lupin Laboratories
- Intercept Pharmaceuticals
- Teva Pharmaceuticals
- Sanofi-Aventis
Highlights of The Alcoholic Hepatitis Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Caspase Protease Inhibitor
- Corticosteroids
- Hemorheologic Agents
- Anabolic Steroids
- Hepatotropic Hormones
- Sulfhydryl Agents
- Others
- By Application:
- Hospitals and Clinics
- Research and Development
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alcoholic Hepatitis Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alcoholic hepatitis is a liver disease caused by excessive drinking. It can lead to cirrhosis, which is the end stage of liver damage. Alcoholic hepatitis treatment focuses on reducing alcohol consumption and managing other health conditions that may be contributing to the disease.
Some of the key players operating in the alcoholic hepatitis therapeutic market are Alkermes, Conatus pharmaceuticals, Dainippon sumitomo pharma, Generon corporation, Immuron limited, Lupin Laboratories, Intercept Pharmaceuticals, Teva Pharmaceuticals, Sanofi-Aventis.
The alcoholic hepatitis therapeutic market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alcoholic Hepatitis Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alcoholic Hepatitis Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alcoholic Hepatitis Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alcoholic Hepatitis Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alcoholic Hepatitis Therapeutic Market Size & Forecast, 2018-2028
4.5.1 Alcoholic Hepatitis Therapeutic Market Size and Y-o-Y Growth
4.5.2 Alcoholic Hepatitis Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Alcoholic Hepatitis Therapeutic Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alcoholic Hepatitis Therapeutic Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Caspase Protease Inhibitor
5.2.3 Corticosteroids
5.2.4 Hemorheologic Agents
5.2.5 Anabolic Steroids
5.2.6 Hepatotropic Hormones
5.2.7 Sulfhydryl Agents
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alcoholic Hepatitis Therapeutic Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alcoholic Hepatitis Therapeutic Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Research and Development
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alcoholic Hepatitis Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alcoholic Hepatitis Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alcoholic Hepatitis Therapeutic Analysis and Forecast
9.1 Introduction
9.2 North America Alcoholic Hepatitis Therapeutic Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alcoholic Hepatitis Therapeutic Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Caspase Protease Inhibitor
9.6.3 Corticosteroids
9.6.4 Hemorheologic Agents
9.6.5 Anabolic Steroids
9.6.6 Hepatotropic Hormones
9.6.7 Sulfhydryl Agents
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alcoholic Hepatitis Therapeutic Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Research and Development
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alcoholic Hepatitis Therapeutic Analysis and Forecast
10.1 Introduction
10.2 Europe Alcoholic Hepatitis Therapeutic Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alcoholic Hepatitis Therapeutic Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Caspase Protease Inhibitor
10.6.3 Corticosteroids
10.6.4 Hemorheologic Agents
10.6.5 Anabolic Steroids
10.6.6 Hepatotropic Hormones
10.6.7 Sulfhydryl Agents
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alcoholic Hepatitis Therapeutic Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Research and Development
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alcoholic Hepatitis Therapeutic Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alcoholic Hepatitis Therapeutic Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alcoholic Hepatitis Therapeutic Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Caspase Protease Inhibitor
11.6.3 Corticosteroids
11.6.4 Hemorheologic Agents
11.6.5 Anabolic Steroids
11.6.6 Hepatotropic Hormones
11.6.7 Sulfhydryl Agents
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alcoholic Hepatitis Therapeutic Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Research and Development
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alcoholic Hepatitis Therapeutic Analysis and Forecast
12.1 Introduction
12.2 Latin America Alcoholic Hepatitis Therapeutic Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alcoholic Hepatitis Therapeutic Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Caspase Protease Inhibitor
12.6.3 Corticosteroids
12.6.4 Hemorheologic Agents
12.6.5 Anabolic Steroids
12.6.6 Hepatotropic Hormones
12.6.7 Sulfhydryl Agents
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alcoholic Hepatitis Therapeutic Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Research and Development
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alcoholic Hepatitis Therapeutic Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alcoholic Hepatitis Therapeutic Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alcoholic Hepatitis Therapeutic Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Caspase Protease Inhibitor
13.6.3 Corticosteroids
13.6.4 Hemorheologic Agents
13.6.5 Anabolic Steroids
13.6.6 Hepatotropic Hormones
13.6.7 Sulfhydryl Agents
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alcoholic Hepatitis Therapeutic Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Research and Development
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alcoholic Hepatitis Therapeutic Market: Competitive Dashboard
14.2 Global Alcoholic Hepatitis Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alkermes
14.3.2 Conatus pharmaceuticals
14.3.3 Dainippon sumitomo pharma
14.3.4 Generon corporation
14.3.5 Immuron limited
14.3.6 Lupin Laboratories
14.3.7 Intercept Pharmaceuticals
14.3.8 Teva Pharmaceuticals
14.3.9 Sanofi-Aventis
